Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement
Key Highlights
- ➤$4.0 million gross financing closed through private placement and warrant inducement
- ➤Operating runway estimated to late 2027 using financing, cash, and expected collections
- ➤Later CDMO work packages could extend operating runway into 2028
- ➤Proceeds will fund customer programs, additional CDMO contracts, and immunotherapy development
Expert Statements
Amir Reichman, Chief Executive Officer of Scinai Immunotherapeutics
“Completing this financing, alongside our recently announced CDMO agreement, strengthens our ability to execute customer programs, develop our CDMO platform and selectively advance our immunotherapy pipeline.”
Amir Reichman, Chief Executive Officer of Scinai Immunotherapeutics
“The recent CDMO agreement establishes a framework for an integrated program with successive phases, and we are looking towards the later work packages to become committed as the program progresses.”
Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement PR Newswire
JERUSALEM, Oct. 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing organization ("CDMO") (link) alongside an immunology-focused therapeutic development platform, today announced the closing of its previously announced private placement of 2,458,334 American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof), each ADS representing 40,000 ordinary shares, together with Series A-1 Warrants to purchase up to 3,687,501 ADSs (the "Private Placement").
Get started
Create a free account to read the full story.